[EN] NOVEL BENZYLTRYPTAMINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE BENZYLTRYPTAMINE
申请人:[en]REUNION NEUROSCIENCE CANADA INC.
公开号:WO2023070228A1
公开(公告)日:2023-05-04
There is disclosed a compound of Formula (I): and any pharmaceutically acceptable salt or zwitterion thereof; wherein: R is hydrogen, methyl or ethyl; R1is hydrogen or C1-C2alkoxy; R2is methyl or a C2-C4group which may be saturated or unsaturated, branched or linear; and R3, R4, R5and R6each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6and R7must be hydrogen, and (ii) R3, R4, R5and R6may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).